🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

210 results for “Ovid” Clear

  1. A matching sterile product (Placebo Ophthalmic Solution) will be provided using the same excipient formulation as the active K-321 product., Ripasudil

    Institut für biomedizinische Analytik NMR-Imaging GmbH

    Fuchs Endothelial Corneal Dystrophy

    phase 3 small molecule active

    1 trial

  2. ARCT-154 Self-Amplifying RNA SARS-CoV-2 Vaccine

    Arcturus Therapeutics Holdings

    COVID-19 Vaccines

    phase 3 mab completed

    1 trial

  3. ARCT-2303

    Arcturus Therapeutics Holdings

    COVID-19

    phase 3 mab completed

    1 trial

  4. Adsorbed COVID-19 (inactivated) Vaccine

    SINOVAC BIOTECH LTD

    COVID-19

    phase 3 mab completed

    1 trial

  5. Arexvy powder and suspension for suspension for injection Respiratory Syncytial Virus (RSV) vaccine (recombinant, adjuvanted), Comirnaty Omicron XBB.1.5 30 micrograms/dose dispersion for injection COVID-19 mRNA Vaccine

    GlaxoSmithKline Biologicals S.A.

    Respiratory Syncytial Virus Infections

    phase 3 small molecule active

    1 trial

  6. Baricitinib

    Eli Lilly Co.

    Covid19 Corona Virus Infection

    phase 3 small molecule active

    1 trial

  7. Benlysta 200 mg solution for injection in pre-filled syringe., Placebo for Belimumab Solution for Injection, 200 mg/mL. The placebo for Belimumab Solution for Injection, 200 mg/mL is provided as a sterile solution for subcutaneous (SC) injection in single-use prefilled syringes.

    GlaxoSmithKline Biologicals S.A.

    Lung Diseases, Interstitial

    phase 3 small molecule active

    1 trial

  8. Bortezomib STADA 2,5 mg/ml Injektionslösung, Dexamethason 0,5 mg JENAPHARM®, Empliciti 400 mg powder for concentrate for solution for infusion., Kyprolis 60 mg powder for solution for infusion, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, -, Nodexon 20 mg tabletes, Imnovid 3 mg hard capsules, Imnovid 4 mg hard capsules, Imnovid 2 mg hard capsules, Nodexon 20 mg tabletės, ELRANATAMAB, Dexamethason 4 mg JENAPHARM®

    Pfizer Ireland Pharmaceuticals Unlimited Company

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  9. COVID-19 Vaccine (Vero cell), Inactivated (Omicron variant)

    SINOVAC BIOTECH LTD

    COVID-19

    phase 3 mab completed

    1 trial

  10. COVID-19 Vaccine,Inactivated

    SINOVAC BIOTECH LTD

    COVID-19

    phase 3 mab completed

    1 trial

  11. CPI-006 2 mg/kg + SOC

    Corvus Pharmaceuticals

    Covid-19

    phase 3 small molecule terminated

    1 trial

  12. Cannabidiol, pharmaceutically produced with < 5 ppm THC

    Cardiol Therapeutics

    COVID-19

    phase 3 small molecule terminated

    1 trial

  13. Ceftriaxone

    Adaptive Biotechnologies Corp

    Community-acquired Pneumonia, Influenza, COVID-19

    phase 3 small molecule active

    1 trial

  14. Cetirizine

    BRIGHT MINDS BIOSCIENCES INC.

    COVID-19

    phase 3 small molecule terminated

    1 trial

  15. DEXAMETHASONE, Dexamethasonfosfaat Accord 4 mg/ml oplossing voor injectie/infusie, Kyprolis 10 mg powder for solution for infusion, Paracetamol 1000mg Tablets, Imnovid 2 mg hard capsules, Imnovid 1 mg hard capsules, DARZALEX 1800 mg solution for injection, LYNOZYFIC 200 mg concentrate for solution for infusion, Dermodrin 30 mg/2 ml soluție injectabilă, Imnovid 3 mg hard capsules, DEXAMETHASONE, Co-Trimoxazole 80/400mg Tablets, Kyprolis 30 mg powder for solution for infusion, LYNOZYFIC 5 mg concentrate for s

    Pharma Mar S.A.

    Relapsed Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  16. DEXMEDETOMIDINE , 18F-DPA-714

    Pari Pharma GmbH

    Patients who survive a COVID ARDS in intensive care must be weaned off invasive mechanical ventilation as quickly as possible. 60% of these patients present with intensive care delirium, a serious event that causes excess mortality and potential acute and late complications, since 30% of patients who present with delirium develop cognitive sequelae. Severe neuroinflammation is considered to be one of the main pathophysiological mechanisms causing delirium during ventilatory weaning. In addition to its sedative properties, dexmedetomidine has neuroprotective effects. In certain experimental models, it reduces cerebral inflammation by acting directly on the microglial phenotype. The role of this chronic neuroinflammatory state on cognitive capacity and reserve is beginning to emerge in the literature, regardless of the initial stress (surgery, head injury or Alzheimer's-type dementia), and is therefore capable of influencing patients' quality of life. The assessment of this neuroinflammation using non-invasive tools would appear to be of prime importance in the management of post-COVID neuro injured patients, as well as the evaluation of potential neuroprotective agents such as dexmedetomidine.

    phase 3 small molecule active

    1 trial

  17. Dexamethason 8 mg GALEN® Tabletten, Imnovid 1 mg hard capsules, Dexamethasone 2mg Tablets, Dexamethason 8 mg JENAPHARM®, Dexamethasone Tablets BP 2.0mg, Imnovid 4 mg hard capsules

    GlaxoSmithKline Biologicals S.A.

    Relapsed/Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  18. Dexamethason CF 20 mg/ml, injectievloeistof, Imnovid 4 mg hard capsules, ELOTUZUMAB, VELCADE 3.5 mg powder for solution for injection, IXAZOMIB , Dexamethason 4 mg JENAPHARM®, Kyprolis 30 mg powder for solution for infusion, Imnovid 1 mg hard capsules, Imnovid 2 mg hard capsules, Imnovid 3 mg hard capsules, Revlimid 15 mg hard capsules, IXAZOMIB, idecabtagene vicleucel, DARZALEX 20 mg/mL concentrate for solution for infusion, Revlimid 10 mg hard capsules, IXAZOMIB, Revlimid 5 mg hard capsules, Revlimid 25 m

    Celgene Europe Limited

    Multiple myeloma (MM) with at least 2 prior therapies including an immunomodulatory (IMiD) compound and a proteasome inhibitor (PI) and demonstrated disease progression on or within 60 days of completion of the last therapy.

    phase 3 small molecule active

    1 trial

  19. Dociparstat sodium

    Jazz Pharmaceuticals Ireland Limited

    Coronavirus Disease 2019 (COVID-19)

    phase 3 small molecule terminated

    1 trial

  20. Drug Isotretinoin (13 cis retinoic acid ) capsules+standard treatment

    United Therapeutics Europe Ltd

    COVID19

    phase 3 small molecule active

    1 trial

  21. Empliciti 400 mg powder for concentrate for solution for infusion., DARZALEX 1800 mg solution for injection, Alnuctamab, Imnovid 2 mg hard capsules, Alnuctamab, Imnovid 3 mg hard capsules, Imnovid 1 mg hard capsules, Kyprolis 60 mg powder for solution for infusion, Fortecortin® Inject 8 mg Injektionslösung in einer Ampulle, DEXAMETHASONE, Imnovid 4 mg hard capsules

    Celgene Europe Limited

    Relapsed and/or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

  22. Erbitux 5 mg/mL solution for infusion, Ficlatuzumab, Ficlatuzumab, The corresponding placebo for this study is 0.9% Sodium Chloride injection for intravenous administration and this will be provided by the study site (and reimbursed by the Sponsor).

    Pharma Mar S.A.

    Head and Neck Squamous Cell Carcinoma (HNSCC)

    phase 3 small molecule active

    1 trial

  23. FST201 (dexamethasone 0.1% with povidone-iodine 1%)

    Takeda Pharmaceuticals International AG

    Acute Otitis Externa

    phase 3 small molecule completed

    1 trial

  24. Fortecortin® 2 mg Tabletten, Privigen 100 mg/ml solution for infusion, Privigen 100 mg/ml solution for infusion, KIOVIG 100 mg/ml solution for infusion, Imnovid 4 mg hard capsules, Privigen 100 mg/ml solution for infusion, Pomalidomide, KIOVIG 100 mg/ml solution for infusion, Imnovid 1 mg hard capsules, KIOVIG 100 mg/ml solution for infusion, Pomalidomide, Dexamethasone Tablets BP 2.0mg, JNJ-64407564, JNJ-64407564, Pomalidomide, DARZALEX 1800 mg solution for injection, Imnovid 3 mg hard capsules, Dexamethas

    Janssen-Cilag International N.V.

    Relapsed or Refractory Multiple Myeloma

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources